Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life

Pharmacological Reports

Volumn 61, Issue 4, 2009, Pages 673-680

  Jankun, Jerzy ^a,b   Aleem, Ansari M ^a   Struniawski, Radosław ^a,c   Łysiak Szydłowska, Wiesława ^b   Selman, Steven H ^a   Skrzypczak Jankun, Ewa ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

Author keywords

Blood; PAI 1 deficiency; Thromboelastometer; Thrombus lysis; Very long half life PAI 1

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; PLASMINOGEN ACTIVATOR INHIBITOR 1 DEFICIENCY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN DEFICIENCY; THROMBOELASTOGRAPHY; WILD TYPE; YOUNG MODULUS;

EID: 70549096114     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70119-7     Document Type: Article

References (38)

1. TEG 5000 User's Manual Version 4.2 Software, 2006, Haemoscope Corporation.
2. Agren A, Wiman B, Schulman S: Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis, 2007, 18, 657-660. (Pubitemid 47479416)
3. Aso Y: Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci, 2007, 12, 2957-2966.
4. Audenaert AM, Knockaert I, Collen D, Declerck PJ: Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. J Biol Chem, 1994, 269, 19559-19564. (Pubitemid 24233486)
5. Baynard T, Jacobs HM, Kessler CM, Kanaley JA, Fernhall B: Fibrinolytic markers and vasodilatory capacity following acute exercise among men of differing training status. Eur J Appl Physiol, 2007, 101, 595-602. (Pubitemid 47517202)
6. Berkenpas MB, Lawrence DA, Ginsburg D: Molecular evolution of plasminogen activator inhibitor-1 functional stability. Embo J, 1995, 14, 2969-2977.
7. Carmeliet P, Kieckens L, Schoonjans L, Ream B, van Nuffelen A, Prendergast G, Cole M et al.: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest, 1993, 92, 2746-2755.
8. Carr ME, Jr., Krishnamurti C, Alving BM: Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis. Thromb Haemost, 1992, 67, 106-110.
9. Carroll RC, Craft RM, Chavez JJ, Snider CC, Kirby RK, Cohen E: Measurement of functional fibrinogen levels using the Thrombelastograph. J Clin Anesth, 2008, 20, 186-190. (Pubitemid 351698109)
10. Chorostowska-Wynimko J, Świercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther, 2003, 2, 19-28.
11. Declerck PJ, De Mol M, Vaughan DE, Collen D: Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem, 1992, 267, 11693-11696.
12. Declerck PJ, Verstreken M, Collen D: Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemost, 1995, 74, 1305-1309.
13. Drinane MC, Sherman JA, Hall AE, Simons M, Mulligan-Kehoe MJ: Plasminogen and plasmin activity in patients with coronary artery disease. J Thromb Haemost, 2006, 4, 1288-1295. (Pubitemid 43756707)
14. Fay WP, Parker AC, Condrey LR, Shapiro AD: Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood, 1997, 90, 204-208.
15. Gallimore MJ, Harris SL, Tappenden KA, Winter M, Jones DW: Urokinase induced fibrinolysis in thromboelastography: a model for studying fibrinolysis and coagulation in whole blood. J Thromb Haemost, 2005, 3, 2506-2513. (Pubitemid 41727168)
16. Horrevoets AJ: Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. Br J Haematol, 2004, 125, 12-23. (Pubitemid 38453272)
17. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y et al.: Structure of human urokinase plasminogen activator in complex with its receptor. Science, 2006, 311, 656-659.
18. Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ et al.: Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis. Int J Mol Med, 2007, 20, 683-687.
19. Jankun J, Aleem AM, Specht Z, Keck RW, Lysiak-Szydlowska W, Selman SH, Skrzypczak-Jankun E: PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med, 2007, 20, 11-20.
20. Jankun J, Specht Z, Szkudlarek M, Greenfield R, Gaikwad B, Trifonov L, Vaugeois J et al.: Plasminogen activator inhibitor-1 is locked in active conformation and polymerizes upon binding ligands neutralizing its activity. Int J Mol Med, 2006, 17, 437-447.
21. Kohro S, Yamakage M, Omote T, Namiki A: In vitro effects of propofol on blood coagulability and fibrinolysis by the use of thromboelastograph technique. Acta Anaesthesiol Scand, 1999, 43, 217-219.
22. Kuhli C, Luchtenberg M, Scharrer I, Hattenbach LO: Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefes Arch Clin Exp Ophthalmol, 2005, 243, 963-966. (Pubitemid 41631034)
23. Largent V, Deneys V, Brichard B, Chantrain C, Vermylen C: Bleeding diathesis in a child with normal screening tests: think about fibrinolysis. Eur J Pediatr, 2005, 164, 587-588. (Pubitemid 41225066)
24. Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost, 2005, 3, 1894-1904.
25. Mosesson MW, Siebenlist KR, Voskuilen M, Nieuwenhuizen W: Evaluation of the factors contributing to fibrin-dependent plasminogen activation. Thromb Haemost, 1998, 79, 796-801.
26. Nicholl SM, Roztocil E, Davies MG: Plasminogen activator system and vascular disease. Curr Vasc Pharmacol, 2006, 4, 101-116. (Pubitemid 46785385)
27. Pawse AR, Tarachand U: Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy. Indian JExp Biol, 1997, 35, 545-552.
28. Rau JC, Beaulieu LM, Huntington JA, Church FC: Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost, 2007, 5 Suppl 1, 102-115.
29. Sugiki M, Maruyama M, Yoshida E, Mihara H, Kamiguti AS, Theakston DG: Enhancement of plasma fibrinolysis in vitro by jararhagin, the main haemorrhagic metalloproteinase in Bothrops jararaca venom. Toxicon, 1995, 33, 1605-1617. (Pubitemid 26011431)
30. Świercz R, Keck RW, Skrzypczak-Jankun E, Selman SH, Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep, 2001, 8, 463-470.
31. Świercz R, Skrzypczak-Jankun E, Merrell MM, Selman SH, Jankun J: Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep, 1999, 6, 523-526.
32. Takahashi Y, Tanaka T, Minowa H, Ookubo Y, Sugimoto M, Nakajima M, Miyauchi Y et al.: Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency. Int J Hematol, 1996, 64, 61-68. (Pubitemid 26228570)
33. Tucker HM, Mottonen J, Goldsmith EJ, Gerard RD: Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol, 1995, 2, 442-445.
34. Vaughan DE: PAI-1 and atherothrombosis. J Thromb Haemost, 2005, 3, 1879-1883.
35. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD: Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med, 2007, 35, 1821-1828.
36. Zhang ZY, Wang ZY, Fu JX, Dong NZ, Zhang W, Bai X, Ruan CG: [Report of a case of congenital plasminogen activator inhibitor-1 deficiency]. Zhonghua Xue Ye Xue Za Zhi, 2004, 25, 129-131.
37. Zhu Y, Carmeliet P, Fay WP: Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation, 1999, 99, 3050-3055. (Pubitemid 29270436)
38. Zorio E, Gilabert-Estelles J, Espana F, Ramon LA, Cosin R, Estelles A: Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem, 2008, 15, 923-929. (Pubitemid 351736413)